Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pennsylvania
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Admitted to the Hospital of the University of Pennsylvania (HUP) in the past 72 hours.
Current HUP locations are Founders 12, Founders 14, Silverstein 11, and Rhoads 1.
Age 18 years or older.
Type-1 or type-2 diabetes mellitus requiring home basal-bolus insulin therapy administered via subcutaneous injection (not pump).
Patient manages own basal-bolus insulin therapy at home without assistance, including measuring own blood glucose (at least at mealtimes) and administering own subcutaneous insulin.
Patient is willing to use the following insulin products: rapid-acting insulin aspart via insulin pen (NovoLog) and long-acting insulin glargine via vial and syringe (Lantus).
Most recent hemoglobin A1c was measured within past 6 months and was \<7.5%.
Active order for in-hospital basal-bolus or sliding-scale insulin.
Patient is willing and able to record their self-measured blood glucose results, doses of insulin that they self-administer, a food journal, and exercise log.
Clinical care team agrees with study inclusion.
You may not be if
Inpatient order for insulin via subcutaneous infusion (i.e., pump) or intravenous infusion (i.e., drip).
Inability to perform the activities required by the trial.
Primary reason for admission was hyperglycemia, hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma, a psychiatric condition, acute alcohol poisoning, or acute drug ingestion.
Order for a newly-prescribed or increased dose of a previously-prescribed corticosteroid.
Enteral or parenteral nutrition.
Expected length of stay \<48h, as determined by treating physician.
At risk for self-harm, as determined by 1-to-1 status placement.
Pregnant, as recorded on medical record.
Cannot understand, speak, and read English.
Patient does not wish to utilize Novolog and Lantus while in the hospital.
Prior enrollment in this trial.
Do not resuscitate status.
Inability to give written informed consent.
Clinical care team disagrees with study inclusion.
Patient has limited mobility such that they cannot safely access the bedside medication lockbox.
